Hikma Gets FTC Nod For Custopharm Deal – But With Strings Attached
Acquisition Moves Closer To Completion, But Combining Firms Must Lose A Product
Hikma has moved closer to completing a deal worth more than $400m to acquire Custopharm, which promises to bolster its US injectables business. However, the FTC’s approval of the transaction comes with conditions.
You may also be interested in...
Hikma has set out fresh growth forecasts for its injectables business after completing its acquisition of Custopharm. Meanwhile, a slow start to the year for the firm’s generics business amid a “challenging pricing environment” is expected to be followed by higher revenues towards the end of the year.
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.